Lipid nanoparticles
Lipid nanoparticles with cationic lipids and targeted polyalkylene glycol-modified lipids address the challenge of selective nucleic acid delivery to target cells by binding to specific cell surface antigens, improving the efficiency and specificity of mRNA and siRNA delivery to T cells.
WO2026141627A1PCT designated stage Publication Date: 2026-07-02NITTO DENKO CORP
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- NITTO DENKO CORP
- Filing Date
- 2025-12-26
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
Existing lipid nanoparticles face challenges in selectively delivering nucleic acids to target cells, particularly due to the lack of effective targeting mechanisms.
Method used
The development of lipid nanoparticles comprising cationic lipids and targeted polyalkylene glycol-modified lipids, which are linked to a target binding site, enabling selective delivery of nucleic acids to specific cell types such as T cells and hematopoietic stem cells by binding to antigens like CD2, CD3, CD4, CD5, CD6, CD7, CD8, or CD90/CD117.
Benefits of technology
The lipid nanoparticles achieve selective delivery of nucleic acids to target cells, enhancing the efficiency and specificity of mRNA and siRNA delivery to CD4-positive and CD8-positive T cells compared to untargeted carriers.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure JP2025045807_02072026_PF_FP_ABST
Abstract
The purpose of the present invention is to provide lipid nanoparticles capable of efficiently introducing drugs into cells, and constituent lipids of the lipid nanoparticles. Provided are lipid nanoparticles including nucleic acids encapsulated within the lipid nanoparticles, cationic lipids, and targeted polyalkylene glycol-modified lipids linked to a target binding site, wherein the target binding site targets a target site on a target cell.
Need to check novelty before this filing date? Find Prior Art